Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CYBN

Cybin Inc

Dec 11 • 09:40AM ET

10.18

Dollar change -0.14
Percentage change -1.36	%

Healthcare • Biotechnology • Canada • AMEX

Peers: MNMD ATAI CMPS RLMD GHRS AVXL BTAI NBIX BHVN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.98	Insider Own	8.20%	Shs Outstand	19.99M	Perf Week	-2.40%
Market Cap	203.60M	Forward P/E	-	EPS next Y	-4.21	Insider Trans	0.00%	Shs Float	18.36M	Perf Month	-15.17%
Income	-90.86M	PEG	-	EPS next Q	-0.75	Inst Own	47.56%	Short Float	3.57%	Perf Quarter	33.35%
Sales	0.00M	P/S	-	EPS this Y	-1987.78%	Inst Trans	-21.62%	Short Ratio	1.87	Perf Half Y	-10.40%
Book/sh	9.44	P/B	1.08	EPS next Y	-10.19%	ROA	-76.72%	Short Interest	0.66M	Perf Year	-33.44%
Cash/sh	5.71	P/C	1.78	EPS next 5Y	-	ROE	-80.93%	52W Range	6.50 - 19.85	Perf YTD	-34.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-69.33%	ROI	-48.13%	52W High	-48.72%	Beta	-
Dividend TTM	-	Quick Ratio	24.24	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	56.62%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	24.24	EPS Y/Y TTM	14.43%	Oper. Margin	-	RSI (14)	46.92	Volatility	4.43% 10.31%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	95.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-45.98%	Payout	-	Rel Volume	0.57	Prev Close	10.32
Sales Surprise	-	EPS Surprise	-7839.45%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	351.38K	Price	10.18
SMA20	-3.60%	SMA50	-1.80%	SMA200	-12.14%	Trades		Volume	14,765	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-21	Downgrade	Maxim Group	Buy → Hold

Dec-10-24 07:30AM	Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results (Business Wire)
Dec-04-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 (Business Wire)
Nov-18-24 07:00AM	Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder (Business Wire) -8.62%
Nov-14-24 07:30AM	Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 (Business Wire)
Nov-13-24 07:30AM	Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results (Business Wire) -10.26%
07:30AM	Loading…
Oct-31-24 07:30AM	Cybin to Participate at the 2024 Milken Institute Future of Health Summit (Business Wire)
Oct-24-24 07:30AM	Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program (Business Wire)
Oct-03-24 07:30AM	Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 (Business Wire)
Oct-01-24 07:30AM	Cybin Expands Clinical Team to Support CYB003 Phase 3 Program (Business Wire)
Sep-24-24 07:30AM	Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Business Wire)
Sep-19-24 05:38PM	Cybin Provides Corporate Update on Upcoming Clinical Milestones (Business Wire) +10.42% +7.24%
07:26AM	Cybin Announces Completion of Previously Announced Share Consolidation (Business Wire)
Sep-04-24 07:55AM	Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 07:01PM	Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation (Business Wire)
Aug-13-24 07:30AM	Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder (Business Wire)
07:36AM	Loading…
Aug-08-24 07:36AM	Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Aug-07-24 07:30AM	Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-08-24 08:38AM	A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update (Newsfile)
Jun-27-24 12:00PM	What Makes Cybin Inc. (CYBN) a New Buy Stock (Zacks)
Jun-26-24 07:41AM	Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Jun-19-24 07:30AM	Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (Business Wire)
Jun-11-24 09:35AM	Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround (Zacks) +6.83%
07:30AM	Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development (Business Wire)
May-29-24 07:30AM	Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 (Business Wire)
May-14-24 07:30AM	Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase (Business Wire)
May-06-24 08:32AM	Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones (Business Wire) +5.14%
Apr-25-24 07:30AM	Cybin to Participate at the 27th Annual Milken Institute Global Conference (Business Wire)
Apr-18-24 07:30AM	Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry (Business Wire)
Apr-16-24 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder (Business Wire)
Apr-10-24 07:30AM	Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire) -5.90%
11:53AM	Loading…
Mar-19-24 11:53AM	Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
Mar-18-24 07:30AM	Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas (Business Wire)
Mar-15-24 07:30AM	Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder (Business Wire) +7.23%
Mar-14-24 07:30AM	Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design (Business Wire)
Mar-13-24 07:00AM	Announces Oversubscribed Private Placement of U.S. $150 Million (Business Wire)
06:00AM	Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder (Business Wire)
Mar-12-24 10:37PM	Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 (Business Wire) +10.28%
Feb-27-24 07:30AM	Cybin to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 07:45AM	Cybin Reports Third Quarter Financial Results and Recent Business Highlights (Business Wire)
Feb-07-24 07:30AM	Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program (Business Wire) -9.06%
Jan-28-24 05:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-24-24 09:00AM	How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition (PR Newswire)
Jan-23-24 07:30AM	Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder (Business Wire)
Jan-08-24 07:34AM	Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028 (Business Wire)
Jan-04-24 07:32AM	Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs (Business Wire)
Dec-06-23 07:30AM	Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program (Business Wire)
Dec-05-23 07:30AM	Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results (Business Wire)
Nov-30-23 07:30AM	Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses (Business Wire) -6.03%
Nov-20-23 07:30AM	Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City (Business Wire)
Nov-16-23 07:30AM	Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023 (Business Wire)
Nov-15-23 07:30AM	Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting (Business Wire)
Nov-14-23 07:16PM	Cybin Reports Second Quarter Financial Results and Recent Business Highlights (Business Wire)
01:00PM	Cybin Announces Closing of Offering of Units Led by One of the Companys Largest Institutional Shareholders (Business Wire)
Nov-10-23 08:13AM	Canadian Investment Regulatory Organization Trade Resumption - CYBN (PR Newswire) -15.31%
08:05AM	Canadian Investment Regulatory Organization Trading Halt - CYBN (PR Newswire)
08:03AM	Cybin Announces up to US$64 Million Offering of Units (Business Wire)
Nov-03-23 07:40AM	Cybin to Participate at the 2023 Milken Institute Future of Health Summit (Business Wire)
Nov-01-23 03:32PM	Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 (Newsfile) -11.75%
07:30AM	Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline (Business Wire)
Oct-31-23 09:00AM	Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023 (PR Newswire) +6.71%
07:45AM	Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose (Business Wire)
Oct-29-23 05:17PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Oct-26-23 07:30AM	Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs (Business Wire) +12.61%
Oct-25-23 07:30AM	Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program (Business Wire) +11.10%
Oct-23-23 07:33AM	Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics (Business Wire)
Oct-17-23 05:35PM	Small Pharma Obtains Final Order Approving Arrangement (Business Wire) -6.22% -5.57%
Oct-12-23 05:00PM	Cybin Announces Results of Annual and Special Meeting of Shareholders (Business Wire) -5.06%
Oct-06-23 07:30AM	Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit (Business Wire) +5.42%
Oct-04-23 07:30AM	Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire)
Oct-03-23 07:30AM	Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder (Business Wire) -5.40%
Sep-27-23 07:30AM	Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder (Business Wire) -5.64%
Sep-26-23 07:30AM	Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial (Business Wire) -7.99%
Sep-25-23 07:30AM	Cybin to Participate in the Cantor Global Healthcare Conference (Business Wire) +14.62%
Sep-21-23 05:00PM	Cybin Announces Date of Annual and Special Meeting of Shareholders (Business Wire) +15.13% +12.24%
07:30AM	Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder (Business Wire)
Sep-05-23 07:30AM	Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines (Business Wire)
Aug-28-23 01:23PM	Cybin to Acquire Small Pharma Inc. (Newsfile) +5.10%
10:57AM	Canadian Investment Regulatory Organization Trade Resumption - CYBN (PR Newswire)
09:22AM	Canadian Investment Regulatory Organization Trading Halt - CYBN (PR Newswire)
Aug-23-23 09:37PM	Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million (Business Wire)
Aug-21-23 01:40PM	Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs (News Direct)
Aug-17-23 07:30AM	Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial (Business Wire)
Aug-15-23 07:52AM	Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program (Business Wire) -5.00%
Aug-14-23 07:30AM	Cybin Reports First Quarter Financial Results and Recent Business Highlights (Business Wire)
Aug-04-23 09:46AM	Cybin Announces Closing of Overnight Marketed Public Offering of Units (Business Wire) +10.75%
Aug-02-23 07:30AM	Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder (Business Wire) -8.52%
Aug-01-23 09:32AM	Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units (Business Wire) -20.73%
Jul-31-23 06:29PM	Cybin Announces Overnight Marketed Public Offering of Units (Business Wire)
Jul-27-23 07:30AM	Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-26-23 07:30AM	Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder (Business Wire)
Jul-24-23 07:55AM	Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder (PR Newswire)
Jul-20-23 05:01PM	Cybin Announces Publication of Sponsored Feasibility Study Validating Kernels Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain (Business Wire) -5.08%
08:00AM	Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects (Business Wire)
Jul-17-23 08:44AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-12-23 07:30AM	Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT (Business Wire) +9.09%
Jun-30-23 07:30AM	Cybin to Participate in PSYCH Symposium London 2023 (Business Wire)
Jun-29-23 05:00PM	Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer (Business Wire) +11.52%
Jun-27-23 05:00PM	Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights (Business Wire) +10.00%
07:30AM	Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor (Business Wire)
Jun-21-23 07:30AM	Cybin to Participate in the 2023 MAPS Psychedelic Science Conference (Business Wire) +5.91%

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYBN

Cybin Inc

Upgrade your FINVIZ experience